Rohit Sanjay Laul
Dr. Agarwal’s Eye Hospital
India
Title: Vitrectomy for proliferative diabetic retinopathy, is it enough?
Biography
Biography: Rohit Sanjay Laul
Abstract
Purpose: To find out the effectiveness of vitrectomy with intraoperative bevacizumab injection in pseudophakic patients with proliferative diabetic retinopathy. Material & Method: A total of 45 pseudophakic eyes of 45 patients with proliferative diabetic retinopathy underwent standard 23G Pars Plana with intraoperative bevacizumab injection and were followed up for 6 months. Patients age ranged from 46-83years of which 30(66.66%) were males and 15(33.34%) were females. After detailed history taking, they underwent assessment of visual acuity, slit lamp biomicroscopy, fundus examination using 78D lens, indirect ophthalmoscope with 20D lens & B-scan. Standard 23 G pars plana vitrectomy with intraoperative bevacizumab injection was performed in all the cases. Follow up examination was done on next day, at 15 days, 3 months and 6 months following the surgery. The visual acuity, recurrence of hemorrhage and need for another vitrectomy were analysed. Results: The visual acuity improved in 34 eyes(75.55%), after vitrectomy with intraoperative bevacizumab injection. The mean postoperative visual acuity was significantly better than mean preoperative visual acuity. Recurrence of hemorrhage was noted in 4 eyes (8.88%) out of which only 1 eye (2.22%) required another vitrectomy for clearance of hemorrhage. Conclusion: These results demonstrates that vitrectomy with intraoperative bevacizumab injection is an effective procedure in, treating proliferative diabetic retinopathy in pseudophakic patients , reducing the recurrence of hemorrhage and need for another vitrectomy.